US stock futures dip as Trump’s firing of Cook sparks Fed independence fears
Gregory A. Odle, President of Scoliosis at Orthopediatrics Corp (NASDAQ:KIDS), recently executed a stock transaction involving the sale of 5,359 shares. This sale, recorded at a price of $24.86 per share, amounted to a total value of $133,224. The transaction took place on March 18, 2025, with the stock currently trading at $25.34. According to InvestingPro analysis, the company demonstrates strong liquidity with a current ratio of 6.98, despite not being profitable in the last twelve months.
Prior to this sale, Odle acquired 38,773 shares of common stock on March 15, 2025, at no cost, as part of a stock award. Following these transactions, Odle’s direct ownership stands at 148,788 shares, which includes restricted stock awards totaling 93,291 shares. The shares sold were intended to satisfy tax withholding obligations upon the vesting of restricted shares. The company, valued at $614 million, has shown impressive revenue growth of 37.65% and maintains a GOOD financial health score according to InvestingPro, which offers comprehensive analysis and additional insights through its Pro Research Report.
In other recent news, OrthoPediatrics Corporation reported its fourth-quarter 2024 earnings, revealing a significant loss with an EPS of -$0.69, which missed the forecasted -$0.30. However, the company’s revenue of $52.7 million exceeded expectations of $50.72 million, marking a 40% year-over-year increase. Despite the revenue beat, the stock target was cut by Stifel analysts to $32, down from $40, although they maintained a Buy rating. The company’s management highlighted several key sales drivers for 2025, including the potential expansion of the Specialty Bracing franchise and the launch of new products like the PNP Tibia and DF2 Fracture Brace. OrthoPediatrics projects revenue growth between 15-18% for 2025, with expectations of achieving positive free cash flow by the fourth quarter of 2025. The company also reported a strong U.S. Trauma business, supported by recent set deployments, which is anticipated to contribute to further market share gains. Analyst Rick Wise (LON:WISEa) from Stifel expressed optimism about the company’s prospects, citing these developments as indicators of a promising year ahead.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.